Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2014

View Archived Issues

PD-404182 evaluated as an anti-HIV and anti-HSV microbicidal candidate

Autifony Therapeutics awarded grant to support phase IIa study of AUT-00063 for tinnitus

Novel XIAP inhibitors developed by Bristol-Myers Squibb and Ensemble Therapeutics

Nerviano Medical Sciences prepares new RET inhibitors

Pfizer presents novel dopamine D1 receptor agonists

OMP-59R5 plus etoposide is well tolerated in SCLC patients

PENELOPE data: pertuzumab + topotecan + paclitaxel in ovarian cancer

First-in-human results for anti-IGF-I/II antibody BI-836845

COMBI-d: first phase III trial of dabrafenib + trametinib in metastatic melanoma

Researchers patent novel tuberculosis vaccines

LG Life Sciences discloses new GPR40 agonists

Novel agents for HIV infection disclosed by Belgian team

Complexa completes series B financing to support development of CXA-10

KineMed and Pfizer extend research collaboration

Phase II study of fruquintinib initiated in non-small cell lung cancer

Ventana Medical Systems and MedImmune collaborate on PD-L1 assay

Critical Outcome Technologies completes financing round to support lead candidate

Curis re-initiates patient dosing in monotherapy trial of CUDC-427

National Institute of Mental Health recruits participants in study of radioligand [11C]ER-176

Immune Design confirms first patient treated in phase I clinical trial of LV-305

Agalimmune receives milestone payment triggered by phase I trials of Alphaject technology

Revive Therapeutics submits pre-IND package to the FDA for REV-002

FDA grants fast track designation to Epidiolex for Dravet syndrome

Pradaxa approved in E.U. for prevention of deep vein thrombosis and pulmonary embolism

Valeant's Jublia approved in U.S. for onychomycosis

FDA approves Eloctate for hemophilia A

Merck & Co. set to acquire Idenix Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...